Remdesivir improves COVID-19 survival rate - Gilead

06:09 Fri, 01 July

GEO

USD

$ 2.9283

EUR

€ 3.0504

GBP

£ 3.5503

RUB

₽ 0.0542

TRY

₺ 0.0018

AZN

₼ 0.0173

Bitcoin

20,385.9000

Ethereum

1,093.9200

Bitchoin Cash

104.6640

Litecoin

54.9470

XRP

0.3310

30.Oct .2020 11:00

Remdesivir improves COVID-19 survival rate - Gilead

377

Back

Gilead criticised a World Health Organization study that raised doubts about its Covid-19 treatment, insisting that the overnight blockbuster drug does improve survival rates for a large group of hospitalised patients - FT reports.

According to FT, the company mounted the defence of remdesivir as it revealed that the drug, which had not even been approved by the US Food and Drug Administration at the start of the year, generated $873m in revenue in the third quarter.

The WHO study published this month found remdesivir, now known by its brand name Veklury, had little effect on mortality, reducing time in hospital or whether a patient ends up on a ventilator.

Gilead said that the WHO Solidarity trial had failed to distinguish between patients requiring low or high levels of oxygen. Remdesivir improved survival rates for patients on low levels of oxygen, according to an analysis of data from another trial run by the US National Institutes of Health, Gilead said.

Analysts had forecast $1bn of remdesivir sales in the third quarter, and $2.6bn for the full year, as the company signs commercial deals in the US and with governments in other countries - FT reported.

Gilead vaccine